Sandwich vs. Competitive vs. Multiplex: Which Technique Is Shaping the Lateral Flow Assays Market?

The lateral flow assay (LFA) was once known mainly for the pregnancy test. It is now a core part of rapid diagnostics, used in hospitals, living rooms, veterinary clinics, food plants, and drug development labs. Grand View Research sizes the lateral flow assays market at USD 10.2 billion in 2025, and it is still growing now that the COVID-19 testing surge is behind it.

This post covers the forces behind that growth, the numbers, and what the data means for investment diligence and product development.

Key Market Dynamics and Macro Trends

1. Infectious disease threats keep recurring. COVID-19 showed how valuable fast, accessible testing is, and new threats have kept demand alive. The CDC recorded 67 human H5N1 avian influenza cases in 2024, 40 tied to dairy cattle and 23 to poultry farms. Early 2025 brought Ireland's first clade I mpox case and an Ebola outbreak declared in Uganda. Outbreaks like these keep governments and health systems interested in rapid screening tools.
2. Care is moving toward the patient. Point-of-care and home testing are growing, helped by greater self-testing awareness and regulatory approvals. The FDA-authorized BinaxNOW COVID-19 Antigen Self-Test, which delivers results in 15 minutes, is an example of a product that made home testing familiar.
3. Technology is widening what LFAs can do. Better sensitivity and specificity, multiplexing, and smartphone-connected readers have pushed LFAs beyond infectious disease into cardiac markers, fertility, veterinary diagnostics, environmental testing, and food safety. Research is also looking at nanomaterials, CRISPR-based approaches, and DNA amplification to improve performance further.
4. Regulation shapes who wins. The FDA and EMA set high bars for accuracy, quality, and post-market surveillance. Pathways such as the FDA Q-Submission process let developers get early feedback before formal filing, which lowers uncertainty. Reimbursement can change quickly, as Germany showed when it narrowed free testing after the pandemic eased.
5. Regional momentum differs. North America led in 2025 with a 35.4% revenue share, supported by strong healthcare infrastructure and a heavy respiratory-infection burden. Asia Pacific is expanding quickly on rising healthcare spending and wider adoption of rapid tests in emerging economies. In India and Indonesia, healthcare infrastructure is still developing, and urban centers adopt LFAs far faster than rural areas.

Market Size Projections

• 2025 market size: USD 10.2 billion
• 2026 estimated market size: USD 10.6 billion
• 2033 projected market size: USD 17.4 billion
• CAGR (2026–2033): 7.4%

Where the revenue sits (2025 shares):

• Product: Kits and reagents led with 66.6% and are projected to grow fastest. Lateral flow readers, especially digital and mobile ones, are also poised for strong growth.
• Application: Clinical testing held 74.2%. Drug development and quality testing is projected to grow at about 7.99% CAGR.
• Technique: Sandwich assays led with 38.6%, valued for accuracy, low cost, and ease of use. Multiplex detection is expected to grow fastest.
• End use: Hospitals and clinics led with 34.9%. Diagnostic laboratories are expected to grow fastest, and home care is rising on demand for convenient self-testing.

Want to go deeper? The full report covers segment-level forecasts for 2021–2033 across 20+ countries, plus company profiles and competitive analysis. Download Free Sample

Investment Diligence: What to Look For

The overall growth rate is moderate and steady. The most useful diligence questions concern where within the market the growth is concentrated.

• Post-pandemic durability. Separate revenue tied to COVID-era testing from revenue in structurally growing areas such as STIs, TB, cardiac markers, veterinary use, and food safety. A portfolio that has diversified beyond respiratory testing is better positioned.
• Consolidation. Deal activity is steady. In January 2025, bioMérieux agreed to acquire SpinChip Diagnostics, a Norwegian immunoassay platform company, to strengthen its point-of-care capabilities. Targets with differentiated platforms or readers can attract strategic buyers.
• Recurring versus one-time revenue. Kits and reagents account for two-thirds of the market. Look at how a business pairs consumables with readers or digital platforms, since that can build customer stickiness.
• Regulatory readiness. Check clearance history, quality systems, and experience with the FDA and EMA. Regulatory execution is often what separates a promising assay from a commercial one.
• Geographic exposure. Weigh North America's scale against faster-growing markets, and check each region's reimbursement and procurement dynamics.
• Competitive landscape. The market includes large diagnostics players such as Abbott, Roche, Bio-Rad, Siemens Healthineers, bioMérieux, BD, QuidelOrtho, and Qiagen. A smaller company should have a clear niche or technology edge.

Product Development: Where the Opportunities Are

• Multiplexing. Detecting several targets from one small sample suits syndromic respiratory panels, complex diagnoses, and high-volume food and feed contaminant screening.
• Digital integration. Smartphone readers and cloud-connected devices can add quantification, record-keeping, and reporting to a simple strip. This moves LFAs from a yes/no answer toward data.
• Sensitivity upgrades. Nanoparticle labels and signal-amplification strategies close the performance gap with lab-based methods. Design features like the hook line in Gold Standard Diagnostics' SENSIStrip Gluten test help avoid false negatives in heavily contaminated samples.
• Non-invasive sample types. Abingdon Health's saliva-based pregnancy self-test for Boots shows that new sample formats and retail partnerships can open consumer segments.
• Adjacent applications. Therapeutic drug monitoring, drug authentication, allergen detection, and veterinary diagnostics are growing areas where LFAs offer cost and speed advantages.
• Home-use design. For self-testing, usability, clear result interpretation, and regulatory strategy need to be built in from the start.

The Bottom Line

The lateral flow assays market is not an outbreak-driven spike. It is a maturing market growing from USD 10.2 billion in 2025 toward USD 17.4 billion by 2033, with the best opportunities in multiplexing, digital readers, home testing, and expanding non-clinical applications. Investors and product teams that look beneath the headline CAGR will find the clearest advantage.

Have a question about the market, your target segment, or your investment thesis? Speak directly with the report's research team to get clarity on the data and how it applies to your plans. Speak to Analyst